Canopy Growth (CGC) Liabilities from Discontinued Operations (2022 - 2023)

Canopy Growth (CGC) posted Liabilities from Discontinued Operations of 13894446.86 for Q3 2023, up 449.72% sequentially from 2527542.48 in Q1 2023.

Canopy Growth (CGC) Liabilities from Discontinued Operations (2022 - 2023) Analysis & Trends

Canopy Growth has reported Liabilities from Discontinued Operations for 2 years, with the latest figure at 13894446.86 in Q3 2023.

Quarterly Liabilities from Discontinued Operations changed N/A year-over-year to 13894446.86 in Q3 2023, while the trailing twelve-month figure through Sep 2023 was 13894446.86 (changed N/A YoY) and the FY2023 annual result came in at 2527542.48, changed N/A from the prior year.
Liabilities from Discontinued Operations rose to 13894446.86 in Q3 2023 per CGC's latest filing, from 2527542.48 in the prior quarter.
Over five years, Liabilities from Discontinued Operations peaked at 13894446.86 in Q3 2023 and troughed at 2527542.48 in Q1 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.89 Bn	42.93 Bn	-
2	Teva Pharmaceutical Industries	42.98 Bn	39.33 Bn	2.15 Bn
3	Zoetis	31.54 Bn	29.86 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.61 Bn	22.81 Bn	5.10 Bn
5	United Therapeutics	22.15 Bn	19.48 Bn	683.80 Mn
6	Viatris	18.75 Bn	17.86 Bn	1.46 Bn
7	Neurocrine Biosciences	15.56 Bn	15.17 Bn	935.80 Mn
8	Elanco Animal Health	11.74 Bn	11.21 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.11 Bn	9.95 Bn	-
10	Canopy Growth	441.27 Mn	194.25 Mn	16.08 Mn

Download Data